Evoke Pharma (EVOK) announced that a joint stipulation of dismissal has been filed in the GIMOTI patent infringement case in the United States District Court for the District of New Jersey. The filing of the stipulation arises from Teva Pharmaceuticals (TEVA) and Teva Pharmaceuticals USA’s conversion from a Paragraph IV certification to a Paragraph III certification. A paragraph III Abbreviated New Drug Application is not eligible for approval until the last expiration date of current and potential future orange book listed patents for the reference listed drug in conjunction with appropriate FDA review. In addition, no future ANDA filer will be eligible to receive 180-day generic exclusivity for an ANDA that references GIMOTI. This first-to-file regulatory pathway is typically highly sought after by generic firms.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EVOK:
- Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti
- Evoke abstract accepted at AMCP meeting
- Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023
- USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis
- Evoke Pharma announces USPTO granted new patent covering GIMOTI